Over the past 25 years, TROG Cancer Research has recorded 220 publications in national and international journals. View our current list of publications below.
| Month/Year published | TROG Number | Acronym | Tumour | Citation | Category | Journal |
|---|---|---|---|---|---|---|
| 13/09/2024 | 8.08 | TOPGEAR | Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. N Engl J Med. 2024 Sep 14. doi: 10.1056/NEJMoa2405195. Epub ahead of print. PMID: 39282905. | A | New England Journal of Medicine | |
| 08/07/2024 | 21.07 | SOCRATES | Wigg, A., Tibballs, J., Woodman, R. et al. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). BMC Cancer 24, 813 (2024). https://doi.org/10.1186/s12885-024-12504-2 | A | BMC Cancer | |
| 05/07/2024 | 17.02 | OUTRUN | CNS | Robledo KP, Lefresne S, Soon YY, Sahgal A, Pinkham MB, Nichol A, Soo RA, Parmar A, Hegi-Johnson F, Doherty M, Solomon BJ, Shultz DB, Tham IW, Sacher AG, Tey J, Leong CN, Koh WY, Huang Y, Ang YLE, Low J, Yong C, Lim MC, Tan AP, Lee CK, Ho C. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. BMJ Open. 2024 Jul 5;14(7):e078335. doi: 10.1136/bmjopen-2023-078335. PMID: 38969367. | A | BMJ open |
| 25/03/2024 | 15.03 | FASTRACK II | Genitourinary | Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. PMID: 38423047. | A | Lancet Oncology |
| 11/03/2024 | 18.06 | FIG | CNS | Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. [18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. PMID: 38585372; PMCID: PMC10998205. | A | Physics and Imaging in Radiation Oncology |
| 06/03/2024 | 12.02 | PET-LAB | Breast | PET Scans for Locally Advanced Breast Cancer and Diagnostic MRI to determine the extent of operation and Radiotherapy (PET LABRADOR) TROG 12.02. doi:10.31488/bjcr.190 | A | British Journal of Cancer Research |
| 05/02/2024 | 16.02 | Local HER-O | Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02). Breast. 2024 Feb 5;74:103675. doi: 10.1016/j.breast.2024.103675. Epub ahead of print. PMID: 38340685. | A | The Breast | |
| 01/01/2024 | 18.06 | FIG | Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. PMID: 38181810. | A | The Lancet Oncology | |
| 25/12/2023 | 21.12 | ASPIRE | Khong J, Tee H, Gorayski P, Le H, Penniment M, Jessop S, Hansford J, Penfold M, Green J, Skelton K, Saran F. Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research. J Med Imaging Radiat Oncol. 2023 Dec 25. doi: 10.1111/1754-9485.13614. Epub ahead of print. PMID: 38146017. | B | Journal Of Medical Imaging And Radiation Oncology | |
| 21/11/2023 | 17.03 | LARK | Liver | Sengupta C, Nguyen DT, Moodie T, Mason D, Luo J, Causer T, Liu SF, Brown E, Inskip L, Hazem M, Chao M, Wang T, Lee YY, van Gysen K, Sullivan E, Cosgriff E, Ramachandran P, Poulsen P, Booth J, O'Brien R, Greer P, Keall P. The first clinical implementation of real-time 6 degree-of-freedom image-guided radiotherapy for liver SABR patients. Radiother Oncol. 2023 Nov 24;190:110031. doi: 10.1016/j.radonc.2023.110031. Epub ahead of print. PMID: 38008417. | A | Radiotherapy and Oncology |
| 21/10/2023 | 13.01 | SAFRON II | Lung | Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II). Int J Radiat Oncol Biol Phys. 2023 Oct 21:S0360-3016(23)08005-7. doi: 10.1016/j.ijrobp.2023.09.052. Epub ahead of print. PMID: 37871885. | A | International Journal of Radiation Oncology, Biology, Physics |
| 04/10/2023 | 3.04 | RADAR | Ong, W. L., Nikitas, J., Joseph, D., Steigler, A., Millar, J., Valle, L., . . . Kishan, A. U. (2023). Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. International Journal of Radiation Oncology Biology Physics. doi:10.1016/j.ijrobp.2023.09.051 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/10/2023 | 3.04 | RADAR | Ong, W. L., Nikitas, J., Joseph, D. J., Steigler, A., Denham, J. W., Millar, J. L., . . . Kishan, A. U. (2023). Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR).. Int J Radiat Oncol Biol Phys, 117(2S), S93-S94. doi:10.1016/j.ijrobp.2023.06.424 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 11/08/2023 | 18.06 | FIG | CNS | (EDITORIAL) Barry N, Francis RJ, Ebert MA, Koh ES, Rowshanfarzad P, Hassan GM, Kendrick J, Gan HK, Lee ST, Lau E, Moffat BA, Fitt G, Moore A, Thomas P, Pattison DA, Akhurst T, Alipour R, Thomas EL, Hsiao E, Schembri GP, Lin P, Ly T, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Bailey D, Cook O, Whitehead A, Dykyj R, Rossi A, Grose A, Scott AM. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. Eur J Nucl Med Mol Imaging. 2023 Aug 11. doi: 10.1007/s00259-023-06371-5. Epub ahead of print. PMID: 37563351. | A | European Journal of Nuclear Medicine and Molecular Imaging |
| 04/08/2023 | 18.06 | FIG | CNS | Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, Lau E, Khasraw M, Nowak AK, Bailey DL, Moffat BA, Fitt G, Hicks RJ, Coffey R, Verhaak R, Walsh KM, Barnes EH, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas PA, Roach P, Back M, Leonard R, Scott AM. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open. 2023 Aug 4;13(8):e071327. doi: 10.1136/bmjopen-2022-071327. PMID: 37541751; PMCID: PMC10407346. | A | BMJ Open |
| 04/08/2023 | 18.06 | FIG | CNS | Langen KJ, Galldiks N, Lohmann P, Mottaghy FM. Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3817-3819. doi: 10.1007/s00259-023-06426-7. PMID: 37682302; PMCID: PMC10611633. | A | European Journal of Nuclear Medicine and Molecular Imaging |
| 03/08/2023 | 6.01 | LGG | Central Nervous System | Kros JM, Rushing E, Uwimana AL, Hernández-Laín A, Michotte A, Al-Hussaini M, Bielle F, Mawrin C, Marucci G, Tesileanu CMS, Stupp R, Baumert B, van den Bent M, French PJ, Gorlia T. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Neuro Oncol. 2023 Aug 3;25(8):1443-1449. doi: 10.1093/neuonc/noac282. PMID: 36571817; PMCID: PMC10398806. | B | Neuro Oncology |
| 18/07/2023 | ` | ` | Nguyen H, Montgomery R, Sundaresan P. Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials. J Med Imaging Radiat Oncol. 2023 Jul 16. doi: 10.1111/1754-9485.13564. Epub ahead of print. PMID: 37454368. | ` | International Journal of Radiation Oncology, Biology, Physics | |
| 09/05/2023 | 14.02 | RAIDER | GU | Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, Choudhury A, Foroudi F, Gribble H, Henry A, Hilman S, Hindson B, Lewis R, Muthukumar D, McLaren DB, McNair H, Nikapota A, Olorunfemi A, Parikh O, Philipps L, Rimmer Y, Syndikus I, Tolentino A, Varughese M, Vassallo-Bonner C, Webster A, Griffin C, Hall E. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clin Oncol (R Coll Radiol). 2023 Sep;35(9):586-597. doi: 10.1016/j.clon.2023.05.002. Epub 2023 May 9. PMID: 37225552. | A | Clinical Oncology |
| 21/04/2023 | 9.02 | CHISEL | Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. PMID: 37087060. | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/12/2022 | 13.01 | SAFRON II | Lung | Lourenco RA, Khoo T, Crothers A, Haas M, Montgomery R, Ball D, Bressel M, Siva S. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):968-976. doi: 10.1016/j.ijrobp.2022.01.024. Epub 2022 May 27. PMID: 36395809. | A | International Journal of Radiation Oncology, Biology, Physics |
| 01/11/2022 | 18.06 | FIG | CNS | Koh ES, Francis RJ, Ebert M, Gan H, Lee ST, Lau E, Moore A, Grose A, Rossi A, Ng SP, Yap J, Ly T, Lin P, Pinkham MB, Ngai S, Yu C, Gorayski P, Le H, Kirkwood ID, Vallat W, Syed F, Krishna D, Khan S, Gill S, Thomas E, Back M, Barnes EH, Moffat BA, Scott F, Adda L, Foroudi F, Lourenco RDA, Nowak AK, Bailey DL, Scott AM. NIMG-49. A PROSPECTIVE, MULTI-CENTRE TRIAL OF FET-PET IN GLIOBLASTOMA PATIENTS - THE TROG 18.06 FIG STUDY: KEY ASPECTS OF IMAGING AND RADIATION ONCOLOGY CREDENTIALING. Neuro Oncol. 2021 Nov 12;23(Suppl 6):vi140. doi: 10.1093/neuonc/noab196.547. PMCID: PMC8598843. | A | Neuro Oncology Open Access |
| 06/08/2022 | 7.01 | DCIS | Breast | Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. PMID: 35934006. | A | The Lancet |
| 02/08/2022 | 12.01 | HPV OROPHARYNX | Head and Neck | McDowell L, Rischin PD, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Fua T, Lin C, Liu C, Corry J. Patient- and clinician-reported outcomes in human papillomavirus-associated tonsillar carcinoma treated with unilateral and bilateral intensity-modulated radiotherapy - a substudy from TROG12.01. Int J Radiat Oncol Biol Phys. 2022 Aug 9:S0360-3016(22)03089-9. doi: 10.1016/j.ijrobp.2022.08.006. Epub ahead of print. PMID: 35961477. | A | Red Journal |
| 11/07/2022 | 3.04 | RADAR | Ma, T. M., Chu, F. I., Sandler, H., Feng, F. Y., Efstathiou, J. A., Jones, C. U., . . . Kishan, A. U. (2022). Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). European Urology, 82(5), 487-498. doi:10.1016/j.eururo.2022.07.011 | A | European Urology | |
| 03/07/2022 | 3.04 | RADAR | Kishan, A. U., Wang, X., Sun, Y., Romero, T., Michalski, J. M., Ma, T. M., . . . Spratt, D. E. (2022). High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. European Urology, 82(1), 106-114. doi:10.1016/j.eururo.2022.04.003 | A | European Urology | |
| 17/06/2022 | Lehmann J, Hussein M, Barry M, Siva S, Moore A, Chu M, Diez P, Eaton D J, Harwood J, Lonski P, Mackonis E C, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen T S, Subramanian B, Greer P B, Clark C H. A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. Radiotherapy and Oncology. 2022 April; 171 (5). DOI:10.1016/j.radonc.2022.04.019 | na | Radiotherapy and Oncology | |||
| 16/06/2022 | 14.04 | HART | Breast | Kron T, Bressel M, Lonski P, Hill C, Mercieca-Bebber R, Ahern V, Lehman M, Johnson C, Latty D, Ward R, Miller D, Banjade D, Morriss D, De Abreu Lourenco R, Woodcock J, Montgomery R, Lehmann J, Chua BH. TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients. Clin Oncol (R Coll Radiol). 2022 Sep;34(9):e410-e419. doi: 10.1016/j.clon.2022.05.020. Epub 2022 Jun 16. PMID: 35717318. | A | Clinical Oncology |
| 13/05/2022 | 8.03 | RAVES | Genitourinary | van Gysen K, Kneebone A, Le A, Wu K, Haworth A, Bromley R, Hruby G, O'Toole J, Booth J, Brown C, Pearse M, Sidhom M, Wiltshire K, Tang C, Eade T. Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. Phys Imaging Radiat Oncol. 2022 May 13;22:91-97. doi: 10.1016/j.phro.2022.05.004. PMID: 35602546; PMCID: PMC9117914. | A | Physics and Imaging in Radiation Oncology |
| 04/05/2022 | 12.01 | HPV OROPHARYNX | oropharyngeal | Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ; Trans-Tasman Radiation Oncology Group and the De-ESCALaTE HPV Trial Group. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Ann Oncol. 2022 Aug;33(8):804-813. doi: 10.1016/j.annonc.2022.04.074. Epub 2022 May 4. PMID: 35525376. | A | Annals of Oncology |
| 04/04/2022 | 3.04 | RADAR | Delahunt, B., Steigler, A., Atkinson, C., Christie, D., Duchesne, G., Egevad, L., . . . Denham, J. W. (2022). Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology, 54(1), 49-54. doi:10.1016/j.pathol.2021.11.004 | A | Pathology | |
| 03/03/2022 | Chang D, Moore A, van Dyk S, Khaw P. Why Quality Assurance is Necessary in Gynecologic Radiation Oncology. Int J Gynecol Cancer. 2022 Mar;32(3):402-406. doi: 10.1136/ijgc-2021-002534. | na | International Journal of Gynecological Cancer | |||
| 01/03/2022 | 12.01 | HPV OROPHARYNX | Head and Neck | McDowell L, Bressel M, King MT, Corry J, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Rischin D. Patient-report symptom severity, health-related quality of life and emotional distress trajectories during and after radiotherapy for HPV-associated oropharyngeal cancer: a XXXX.XXXX secondary analysis. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00199-2. doi: 10.1016/j.ijrobp.2023.02.041. Epub ahead of print. PMID: 36868523. | A | International Journal of Radiation Oncology, Biology, Physics |
| 09/02/2022 | 14.02 | RAIDER | GU | Webster A, McNair HA, Hansen VN, Lewis R, Patel E, Miles E, Hall E, Hafeez S, Huddart R; RAIDER, HYBRID Trial Management Groups. Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. Tech Innov Patient Support Radiat Oncol. 2022 Feb 9;21:31-35. doi: 10.1016/j.tipsro.2022.01.002. PMID: 35198744; PMCID: PMC8841376. | B | Technical Innovations & Patient Support in Radiation Oncology |
| 09/02/2022 | 14.02 | RAIDER | GU | Webster A, McNair HA, Hansen VN, Lewis R, Patel E, Miles E, Hall E, Hafeez S, Huddart R; RAIDER, HYBRID Trial Management Groups. Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. Tech Innov Patient Support Radiat Oncol. 2022 Feb 9;21:31-35. doi: 10.1016/j.tipsro.2022.01.002. PMID: 35198744; PMCID: PMC8841376. | A | Technical Innovations & Patient Support in Radiation Oncology |
| 01/02/2022 | 8.04 | PORTEC-3 | Gynaecologic | Wortman BG, Post CCB, Powell ME, Khaw P, Fyles A, D'Amico R, Haie-Meder C, Jürgenliemk-Schulz IM, McCormack M, Do V, Katsaros D, Bessette P, Baron MH, Nout RA, Whitmarsh K, Mileshkin L, Lutgens LCHW, Kitchener HC, Brooks S, Nijman HW, Astreinidou E, Putter H, Creutzberg CL, de Boer SM. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):390-399. doi: 10.1016/j.ijrobp.2021.09.042. Epub 2021 Oct 2. PMID: 34610387. | C | International Journal of Radiation Oncology, Biology, Physics |
| 20/01/2022 | Multi | GU | Kishan AU, Steigler A, Denham JW, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022;8(3):e216871. doi:10.1001/jamaoncol.2021.6871 | NA | JAMA Oncology | |
| 20/01/2022 | 3.04 | RADAR | Kishan, A. U., Steigler, A., Denham, J. W., Zapatero, A., Guerrero, A., Joseph, D., . . . Romero, T. (2022). Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncology, 8(3). doi:10.1001/jamaoncol.2021.6871 | A | JAMA Oncology | |
| 17/01/2022 | 3.04 | RADAR | Kishan, A. U., Sun, Y., Hartman, H., Pisansky, T. M., Bolla, M., Neven, A., . . . Spratt, D. E. (2022). Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. The Lancet Oncology, 23(2), 304-316. doi:10.1016/S1470-2045(21)00705-1 | A | The Lancet Oncology | |
| 10/01/2022 | Multi | GU | Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb;23(2):304-316. doi: 10.1016/S1470-2045(21)00705-1. Epub 2022 Jan 17. PMID: 35051385. | NA | Lancet Oncology | |
| 11/12/2021 | 8.04 | PORTEC-3 | Gynaecologic | Khaw P, Do V, Lim K, Cunninghame J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. Clin Oncol (R Coll Radiol). 2022 Mar;34(3):198-204. doi: 10.1016/j.clon.2021.11.015. Epub 2021 Dec 11. PMID: 34903431. | C | Clinical Oncology |
| 15/11/2021 | 12.01 | HPV OROPHARYNX | oropharyngeal | Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Herschtal A, Fisher R, Fua T, Lin C, Liu C, Hughes BGM, McGrath M, McDowell L, Corry J. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):876-886. doi: 10.1016/j.ijrobp.2021.04.015. Epub 2021 Jun 4. PMID: 34098030. | A | International Journal of Radiation Oncology, Biology, Physics |
| 01/11/2021 | 3.04 | RADAR | Kishan, A. U., Sun, Y., Pisansky, T. M., Bolla, M., Steigler, A., Denham, J. W., . . . Spratt, D. E. (2021). Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer. International journal of radiation oncology, biology, physics, 111(3). doi:10.1016/j.ijrobp.2021.07.046 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/11/2021 | 3.04 | RADAR | Kishan, A. U., Romero, T., Wang, X., Pisansky, T. M., Roach, M., Bolla, M., . . . Spratt, D. E. (2021). Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials. International journal of radiation oncology, biology, physics, 111(3), S78-S79. doi:10.1016/j.ijrobp.2021.07.190 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/10/2021 | 13.01 | SAFRON II | Lung | Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145. | A | JAMA |
| 29/08/2021 | 13.01 | SAFRON II | Lung | Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. Published online August 29, 2021. doi:10.1001/jamaoncol.2021.2939 | A | JAMA Oncology |
| 19/08/2021 | 18.04 | MASTERPLAN | Pancreas | Oar, Andrew et al. “AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.” BMC cancer vol. 21,1 936. 19 Aug. 2021, doi:10.1186/s12885-021-08666-y | C | BMC Cancer |
| 01/08/2021 | 15.03 | FASTRACK II | Genitourinary | Hardcastle N, Cook O, Ray X, Moore A, Moore KL, Pryor D, Rossi A, Foroudi F, Kron T, Siva S. Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. Radiat Oncol. 2021 Aug 3;16(1):142. doi: 10.1186/s13014-021-01820-7. PMID: 34344402; PMCID: PMC8330099. | A | Radiation Oncology |
| 01/08/2021 | 07.01/11.03 | PROM | Genitourinary | Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, Chan AW, Basch E, Bell J, Bennett A, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck AC, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis B, Martin L, Mitchell S, Morel T, Nelson L, Norquist J, O'Connor D, Palmer M, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105. PMID: 34193486; PMCID: PMC8246371. | A | BMJ open |
| 11/07/2021 | 11.03 | P_LUNG GP | Lung | Lehman M, Bernard A, See A, King M, Michael M. A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial. Pract Radiat Oncol. 2021 Jul-Aug;11(4):252-263. doi: 10.1016/j.prro.2020.11.009. Epub 2020 Nov 30. PMID: 33271352. | A | Practical Radiation Oncology |
| 11/06/2021 | 17.06 | SC24 | Central Nervous System | Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. Epub 2021 Jun 11. PMID: 34126044. | B | Lancet |
| 06/06/2021 | GHG | NA | Lehman J. Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency | NA | Journal of Radiation Oncology | |
| 05/05/2021 | 6.01 | LGG | Central Nervous System | Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, Tzuk-Shina T, Lucas A, Freixa SV, Golfinopoulos V, Gorlia T, Hottinger AF, Stupp R, Baumert BG. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. Neuro Oncol. 2021 May 5;23(5):803-811. doi: 10.1093/neuonc/noaa252. PMID: 33130890; PMCID: PMC8099470. | B | Neuro Oncology |
| 01/05/2021 | 5.02 | MGMZL | Gastrointestinal | MacManus MP, Roos D, O'Brien P, Capp A, Wirth A, Tsang R, Bressel M, Lade S, Seymour JF. Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. Eur J Cancer. 2021 Jun 4;152:129-138. | A | European Journal of Cancer |
| 01/04/2021 | 17.03 | LARK | Liver | Lee, Y.Y.D., Nguyen, D.T., Moodie, T. et al. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. BMC Cancer 21, 494 (2021). | A | BMC Cancer |
| 01/03/2021 | 8.04 | PORTEC-3 | Gynaecologic | Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger N(P)B, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, Jürgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Smit VTHBM, Putter H, Creutzberg CL. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial. Int J Radiat Oncol Biol Phys. 2021 Mar; 109(4):975-86. | C | International Journal of Radiation Oncology Biology Physics |
| 09/02/2021 | 14.02 | RAIDER | GU | Webster A, Hafeez S, Lewis R, Griffins C, Warren-Oseni K, Patel E, Hansen VN, Hall E, Huddart R, Miles E, McNair HA. The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance. Clin Oncol (R Coll Radiol). 2021 Jul;33(7):461-467. doi: 10.1016/j.clon.2021.02.009. Epub 2021 Mar 23. PMID: 33766503. | B | Clinical Oncology |
| 01/02/2021 | 9.01 | PROARCT | Gastrointestinal | Ng SP, Chu J, Chander S, Bressel M, McKendrick J, Wong R, Steel M, Murray WK, Leong T, Heriot A, Michael M, Ngan SY. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiother Oncol. 2021 Feb; 155:27-32. | A | Radiotherapy and Oncology |
| 01/01/2021 | 14.03 | EORTC 1219 | Nijhuis H, van Rooij W, Gregoire V, Overgaard J, Slotman BJ, Verbakel WF, Dahele M. Investigating the potential of deep learning for patient-specific quality assurance of salivary gland contours using EORTC-1219-DAHANCA-29 clinical trial data. Acta Oncol. 2021 May;60(5):575-581. doi: 10.1080/0284186X.2020.1863463. Epub 2021 Jan 11. PMID: 33427555. | B | Acta Oncologica | |
| 01/01/2021 | 96.01 | - | Genitourinary | Kumar M, Steigler A and Denham JW. The value of combined androgen blockade in the neo-adjuvant treatment of localised prostate cancer – the jury must remain out. (Letter to the Editor) J Clin Oncol. 2010 Sep; 28(25):e445-46. | A | Journal of Clinical Oncology |
| 01/12/2020 | 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1304-1318. doi: 10.1016/j.ijrobp.2020.07.030. Epub 2020 Jul 30. PMID: 32739320. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2020 | 12.01 | HPV OROPHARYNX | Head and Neck | Young R, Solomon B, Corry J, Angel C, Kenny L, Porceddu S, Wratten C, Macann A, Jackson J, Herschtal A, Rischin D. Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial – A Trans-Tasman Radiation Oncology Group study. Oral Oncol. 2020 Nov; 110:104988. | A | Oral Oncology |
| 01/10/2020 | 8.03 | RAVES | Prostate | Kneebone A, Fraser-Browne C, Duchesne G, Fisher R, Frydenberg M, Herschtal A, Williams S, Delprado W, Haworth A, Joseph D, Martin J, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Wiltshire K, Woo H, Davis I, Lim T, Pearse M. A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP "RAVES" Trial. Lancet Oncol. 2020 Oct; 21:1331-40. | A | Lancet Oncology |
| 01/10/2020 | 15.01 | SPARK | Genitourinary | Hewson E, Nguyen D, O'Brien R, Poulsen P, Booth J, Greer P, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Hardcastle N, Siva S, Tai K, Keall P. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Radiother Oncol. 2020 Oct; 151: P234-41. | C | Radiotherapy and Oncology |
| 01/10/2020 | 8.03 | RAVES | Prostate | Vale C, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes M, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar M, Tierney J, for the ARTISITC Meta-analysis Group. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020 Oct; 396(10260):P1422-31. | A | The Lancet |
| 01/09/2020 | 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-wise analysis of 3 randomised phase 3 trials. Radioth Oncol. 2020 Sep; 150: 281-92. | A | Radiotherapy and Oncology |
| 01/09/2020 | 3.04 | RADAR | Pancreas | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. Radiother Oncol. 2020 Sep;150:281-292. doi: 10.1016/j.radonc.2020.07.048. Epub 2020 Jul 31. PMID: 32745667. | A | Radiotherapy on Oncology |
| 01/07/2020 | 15.01 | SPARK | Genitourinary | Keall P, Nguyen D, O'Brien R, Hewson E, Ball H, Poulsen P, Booth J, Greer P, Hunter P, Wilton L, Bromley R, Kipritidis J, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Arumugam S, Sidhom M, Hardcastle N, Siva S, Tai K, Gebski V, Martin J. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. Int J Radiat Oncol Biol Phys. 2020 Jul; 107(3):530-8. | C | International Journal of Radiation Oncology Biology Physics |
| 01/07/2020 | 5.01 | POST | Head and Neck | Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, Moore A, Veness M, Yao M, Johansen J, Mehanna H, Rischin D, Le QT. Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN). Int J Radiat Oncol Biol Phys. 2020 Jul; 107(4):641-651. | C | International Journal of Radiation Oncology Biology Physics |
| 01/06/2020 | NA | - | NA | McDowell L, Goode S, Sundaresan P. Adapting to a global pandemic through live virtual delivery of a cancer collaborative trial group conference: The TROG 2020 experience. J Med Imaging Radiat Oncol. 2020 Jun; 64(3):414-21. | NA | Journal of Medical Imaging and Radiation Oncology |
| 01/06/2020 | 18.04 | MASTERPLAN | Pancreas | Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng S, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman K, Chang DT, Kneebone A. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiotherapy (SBRT). Pract Radiat Oncol. 2020 Jun; 10(3):e136-46. | C | Practical Radiation Oncology |
| 01/06/2020 | 3.04 | RADAR | Prostate | Panettieri V, Rancati T, Onjukka E, Ebert MA, Joseph DJ, Denham JW, Steigler A, Millar JL. External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Front Oncol. 2020 Jun;10:910. | A | Frontiers in Oncology |
| 01/05/2020 | 7.01 | DCIS | Breast | King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast conserving therapy for non-low risk ductal carcinoma in situ: two-year results of a randomised controlled trial (BIG 3-07/TROG 07.01). Lancet Oncol. 2020 May; 21(5):685?698. | A | Lancet Oncology |
| 01/04/2020 | NA | - | NA | Hardcastle N, Bignell F, Nelms B, Siva S, Kneebone A, Lao L, Cook O, Harris M, Shakeshaft J. The challenge of planning vertebral body SBRT: Optimising target volume coverage. Med Dosim. 2020 Apr; 45(3):302-7. | NA | Medical Dosimetry |
| 01/04/2020 | 16.01 | NIVORAD | Lung | Hardcastle N, Kron T, Cook O, Lehmann J, Mitchell P, Siva S. Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Phys Med. 2020 Apr; 72:16-21 | C | European Journal of Medical Physics |
| 01/01/2020 | 7.01 | DCIS | Breast | Olivotto I, Link E, Phillips C, Whelan T, Bryant G, Kunkler I, Westenberg A, Purohit K, Ahern V, Graham P, Akra M, McArdle O, Ludbrook J, Harvey J, Maduro J, Kirkove C, Gruber G, Martin J, Campbell I, Delaney G, Chua BH; BIG 03-07/TROG 07.01 trial investigators. International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiother Oncol. 2020 Jan; 142:180-5. | A | Radiotherapy and Oncology |
| 01/12/2019 | 11.02 | SCORAD III | Symptom Management | Hoskin P.J, Hopkins K., Misra V, Holt T, Mcmenemin R, Dubois D, Mckinna F, Foran B, Madhavan K, Macgregor C, Bates A, O'rourke N, Lester J.F, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas S.S, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status among Patients with Spinal Canal Compression from Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA. 2019 Dec; 322(21):2084-94. | B | Journal of the American Medical Association |
| 01/12/2019 | 10.02 | RAPID | Breast | Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72. | B | Lancet |
| 01/11/2019 | 15.01 | SPARK | Genitourinary | Hewson E, Nguyen D, O'Brien R, Kim J, Montanaro T, Moodie T, Greer P, Hardcastle N, Eade T, Kneebone A, Hruby G, Hayden A, Turner S, Siva S, Tai K, Hunter P, Sams J, Poulsen P, Booth J, Martin J, Keall P. The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Med Phys. 2019 Nov; 46(11): 4725-37. | C | Medical Physics |
| 01/11/2019 | 8.05 | WBRT | Skin | Hong A, Fogarty G, Dolven-Jacobsen K, Burmeister B, Lo S, Haydu L, Vardy J, Nowak A, Dhillon H, Ahmed T, Shivalingam B, Long G, Menxies A, Hruby G, Drummond K, Mandel C, Middleton M, Reisse C, Paton E, Steel V, Williams N, Scolyer R, Morton R, Thompson J. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 Nov; 37(33): 3132-41. | C | Journal of Clinical Oncology |
| 01/10/2019 | 6.01 | LGG | Central Nervous System | Jaspers J, Mèndez Romero A, Hoogeman MS, van den Bent M, Wiggenraad RGJ, Taphoorn MJB, Eekers DBP, Lagerwaard FJ, Lucas Calduch AM, Baumert BG, Klein M. Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial. Front Oncol. 2019 Oct 1;9:991. doi: 10.3389/fonc.2019.00991. PMID: 31681562; PMCID: PMC6797857. | B | Frontiers in Oncology |
| 01/07/2019 | 15.01 | SPARK | Genitourinary | Wolf J, Nicholls J, Hunter P, Nguyen D, Keall P, Martin J. Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial. Radiother Oncol. 2019 Jul; 136:143-7. | C | Radiotherapy and Oncology |
| 01/07/2019 | 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Jul; 20(9):1273-85. | C | Lancet Oncology |
| 01/06/2019 | 8.03 | RAVES | Prostate | Cloak K, Jameson M, Paneghel A, Wiltshire K, Kneebone A, Pearse M, Sidhom M, Tang C, Fraser-Browne C, Holloway L, Haworth A. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. J Med Imaging Radiat Oncol. 2019 Jun; 63(3):390-8. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/05/2019 | 6.01 | LGG | Central Nervous System | Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):90-100. doi: 10.1016/j.ijrobp.2019.01.003. Epub 2019 Feb 2. PMID: 30716525. | B | International Journal of Radiation Oncology, Biology and Physics |
| 01/04/2019 | 9.02 | CHISEL | Lung | Ball D, Mai T, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vaneski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Le H. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Apr; 20(4):494-503. | A | Lancet Oncology |
| 01/04/2019 | 3.03 | Lymphoma | Wirth A, Prince H, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone J, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Int J Radiat Oncol Biol Phys. 2019 Apr; 103(5):1158-1166 | C | International Journal of Radiation Oncology Biology Physics | |
| 01/02/2019 | 12.03 | EAT | Head & Neck | Britton B, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. Eating As Treatment (EAT): a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy (TROG 12.03). Int J Radiat Oncol Biol Phys. 2019 Feb; 103(2):353-62. | C | International Journal of Radiation Oncology Biology Physics |
| 01/02/2019 | 3.04 | RADAR | Genitourinary | Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna K, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb; 20(2):267-81. | A | Lancet Oncology |
| 19/10/2018 | 14.03 | EORTC 1219 | Tol JP, Dahele M, Gregoire V, Overgaard J, Slotman BJ, Verbakel WFAR. Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance. Radiother Oncol. 2019 Jan;130:75-81. doi: 10.1016/j.radonc.2018.10.005. Epub 2018 Oct 19. PMID: 30348462. | B | Radiotherapy and Oncology | |
| 10/10/2018 | 2.03 | GU | Gogna NK, Duchesne G, O'Brien P, Spry N, Turner S, Matthews J, Borg M, Bauman K, King M, Burmeister E. Trans Tasman Radiation Oncology Group Cancer Research: Phase III - Muscle Invasive Bladder Cancer trial (TROG 02.03): A moral dilemma. J Med Imaging Radiat Oncol. 2018 Oct;62(5):668-670. doi: 10.1111/1754-9485.12752. PMID: 30288941. | A | Journal of Imaging Radiation Oncology | |
| 01/10/2018 | 99.03 | - | Lymphoma | MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour J. A Randomized Trial of Systemic Therapy after involved-field Radiotherapy in patients with Early Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct; 36(29):2918-25. | A | Journal of Clinical Oncology |
| 01/05/2018 | 6.01 | LGG | Central Nervous System | Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC 22033-26033 clinical trial. Eur J Cancer. 2018 May; 94:168-78. | B | European Journal of Cancer |
| 01/05/2018 | 5.01 | POST | Skin | Porceddu S, Bressel M, Poulsen M, Stoneley A, Veness M, Kenny L, Wratten C, Corry J, Cooper S, Fogarty G, Collins M, Collins M, Macann A, Milross C, Penniment M, Liu H, King M, Panizza B, Rischin D. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. J Clin Oncol. 2018 May; 36(13):1275-83. | A | Journal of Clinical Oncology |
| 01/04/2018 | 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Bulsara M, Kearvell R, Joseph D, Denham J. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. J Med Imag Radiat Oncol. 2018 Apr; 62(2):248-55. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/04/2018 | 15.01 | SPARK | Genitourinary | Keall P, Nguyen D, O'Brien R, Caillet V, Hewson E, Poulsen P, Bromley R, Bell L, Eade T, Kneebone A, Martin J, Booth J. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. Radiother Oncol. 2018 Apr; 127(1):6-11. | C | Radiotherapy and Oncology |
| 01/03/2018 | 9.02 | CHISEL | Lung | Kron T, Chesson B, Hardcastle N, Crain M, Clements N, Burns M, Ball D. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. Br J Radiol. 2018 Mar; 91(1085):20170737. | A | British Journal of Radiology |
| 01/02/2018 | 3.01 | Gastrointestinal | Penniment M, De Ieso P, Harvey J, Stephens S, Au H, O'Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):114-24. | A | Lancet Gastroenterolgy and heptalogy | |
| 01/02/2018 | 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Joseph D, Denham J. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radioth Oncol. 2018 Feb; 126(2):249-56. | A | Radiotherapy and Oncology |
| 01/02/2018 | 9.03 | MP3 | Skin | Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. J Med Imag Radiat Oncol. 2018 Feb; 62(3):412-9. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/02/2018 | 8.04 | PORTEC-3 | Gynaecologic | de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb; 19(3):295–309. | C | Lancet Oncology |
| 01/01/2018 | TROG | - | Head and Neck | Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan; 126(1):3-24. | NA | Radiotherapy and Oncology |
| 01/12/2017 | 7.03 | DCIS | Head and Neck | Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncol. 2017 Dec; 75:75-80. | A | Oral Oncology |
| 01/11/2017 | 3.04 | RADAR | Genitourinary | Sharpley, C.F., Bitsika, V., Christie, D.R.H., Bradford, R., Steigler, A., & Denham, J.W. Total Depression and Subtypes in Prostate Cancer Survivors 10 years after treatment. Eur J Cancer Care. 2017 Nov; 26(6):e12630 | A | European Journal of Cancer Care |
| 01/10/2017 | 8.03 | RAVES | Genitourinary | Sundaresan P, Ager B, Turner S, Costa D, Kneebone A, Pearse M, et al. A randomised controlled trial evaluating the utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related decision-making. Radiother Oncol. 2017 Oct; 125(1): 124-29. | A | Radiotherapy and Oncology |
| 01/09/2017 | 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, King M, Bowe S, Stockler M, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017 Sep; 18(9):1192-1201 | C | Lancet Oncology |
| 01/08/2017 | 8.08 | WBRT | Gastrointestinal | Leong T, Smithers M, Haustermans K, Michael M, Gebski V, Miller D, Simes J, Zalcberg J, Boussioutas A, Findlay M, O'Connell R, Verghis J, Willis D, Kron T, Crain M, Murray W, Lordick F, Swallow C, Darling G, Wong R. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG (formerly NCIC CTG). Ann Surg Oncol. 2017 Aug; 24(8): 2252-58 | C | Annals of Surgical Oncology |
| 01/07/2017 | 7.04 | - | Head and Neck | Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4):948-54 | A | International Journal of Radiation Oncology Biology Physics |
| 01/07/2017 | 99.05 | - | Lung | Cox A, Akhurst T, Bressel M, MacManus M, Ball D. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy. Radiother and Oncol. 2017 Jul; 124(1):25-30 | A | Radiotherapy and Oncology |
| 01/07/2017 | 15.01 | SPARK | Genitourinary | Legge K, Greer P, Keall P, Booth J, Arumugam S, Moodie T, Nguyen D, Martin J, O'Connor D, Lehmann J. Technical Note: TROG 15.01 SPARK Trial Multi-Institutional Imaging Dose Measurement. J Appl Clin Med Phys. 2017 Jul; 18(5):358-63 | C | Journal of Applied Clinical Medical Physics |
| 01/06/2017 | 8.01 | PROFIT | Genitourinary | Catton C, Lukka H, Gu C, Martin J, Supiot S, Chung P, Bauman G, Bahary J, Ahmed S, Cheung P, Tai KH, Wu J, Parliament M, Tsakiridis T, Corbett T, Tang C, Days I, Warde P, Craig T, Julian J, Levine M. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun; 35(17):1884-90 | B | Journal of Clinical Oncology |
| 01/04/2017 | 3.04 | RADAR | Genitourinary | Bitska V, Sharpley CF, Bradford R, Steigler A, Denham JW. Measuring Personal and Functional Changes in Prostate Cancer Survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial. Psycho-Oncology. 2017 Apr; 26(4):553-55 | A | Pyscho Oncology |
| 01/04/2017 | 15.01 | SPARK | Genitourinary | Ngyuen D, O'Brien R, Kim J, Huang C, Booth J, Wilton L, Greer P, Legge K, Poulsen P, Martin J, Keall P. The First Clinical Implementation of a Real-Time Six Degree Of Freedom Tracking System For Intrafaction Prostate Motion During Radiation Therapy. Radiother and Oncol. 2017 Apr; 123(1):37-42 | C | Radiotherapy and Oncology |
| 01/03/2017 | 2.02 | - | Head and Neck | Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar; 97(4): 678-86 | A | International Journal of Radiation Oncology Biology Physics |
| 01/03/2017 | 8.02 | GBM | Central Nervous System | Perry J, Laperriere N, O'Callaghan C, Brandes A, Menten J, Phillips C, Fay m, Nishikava R, Carncross J, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Goldinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-course radiation plus temozolomide in elderly patients with glioblastoma. New Engl J Med. 2017 Mar; 376(11):1027-37. | B | New England Journal of Medicine |
| 01/03/2017 | 8.05 | WBRT | Skin | Hong A; Hallock H; Valenzuela M; Lo S; Paton E; Ng D; Dhillon H; Jacobsen K; Reisse C; Fogarty G. Hippocampal avoidance whole brain radiation therapy is associated with preservation of hippocampal volume at six months: a case series. Neurooncol Open Access 2017 Mar; 1:1. | C | Neuro Oncology Open Access |
| 01/02/2017 | 11.01 | SUPREMO | Breast | Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron D, Bartlett J, Bowman A, Piper T, Cunningham C, Canney P, Kunkler I. The BIG 2.04 MRC/EORTC SUPREMO Trial - Pathology quality assurance of a large phase 3 randomised international clinical trial of post mastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Res Treat. 2017 Feb; 163(1):63-9. | B | Breast Cancer Research and Treatment |
| 01/02/2017 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, House MJ, Kennedy A, Matthews J, Joseph DJ, Denham JW. Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface. Int J Radiat Oncol Biol Phys. 2017 Feb; 97(2):420-6 | A | International Journal of Radiation Oncology Biology Physics |
| 01/12/2016 | 3.04 | RADAR | Genitourinary | Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R. Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. Phys Med. 2016 Dec; 32(12):1690-7 | A | Physics Medica |
| 01/11/2016 | 6.01 | LGG | Central Nervous System | Baumert B, Hegi M, Van Den Bent J, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes A, Kantor G, Taphoorn M, Ben Hassel M, Hartmann C, Ryan G, Capper D, Kros J, Kurscheild S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg J, Feuvret L, Reijneveld J, Chinot O, Gijtenbeek J, Rossiter J, Dif N, Balana C, Barvo-Marques J, Clement P, Marosi C, Tzuk-Shina T, Nordal R, Rees J, Lacombe D, Mason W, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1521-32. | B | Lancet Oncology |
| 01/11/2016 | 6.01 | LGG | Central Nervous System | Reijneveld J, Taphoorn M, Coens C, Bromber J, Mason W, Hoang-Xuan K, Ryan G, Beh Assel M, Enting R, Brandes A, Wick A, CHinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulous V, Gorlia T, Bottomley A, Stupp R, Baumert B. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1533-42. | B | Lancet Oncology |
| 01/10/2016 | 3.04 | RADAR | Genitourinary | Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthew J, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016 Oct; 121(1):98-102. | A | Radiotherapy and Oncology |
| 01/10/2016 | 3.04 | RADAR | Genitourinary | Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct; 11(1):144 | A | Radiation Oncology |
| 01/09/2016 | 13.01 | SAFRON II | Lung | Pham D, Hardcastle N, Foroudi F, Kron T, Bressel M, Hilder B, Chesson B, Oates R, Montgomery R, Ball D, Siva S. A Multidisciplinary Evaluation of a Web-based eLearning Training Programme for SAFRON II (TROG 13.01): A Multicentre Randomised Study of Stereotactic Radiotherapy for Lung Metastases. Clin Oncol. 2016 Sep; 28(9):e101-08. | A | Clinical Oncology |
| 01/09/2016 | 8.04 | PORTEC-3 | Gynaecologic | Jameson M, Mcnamara J, Bailey M, Metcalfe P, Holloway L, Foo K, Do V, Mileshkin L, Creutzberg, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imag Radia Oncol. 2016 Sep; 60(4):554-59 | C | Journal of Medical Imaging and Radiation Oncology |
| 01/08/2016 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Kennedy A, Joseph DJ, Denham JW. Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting. Radiother Oncol. 2016 Aug; 120(2):339-45 | A | Radiotherapy and Oncology |
| 01/07/2016 | 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 Jul; 17(8):1114-26. | C | Lancet Oncology |
| 01/06/2016 | 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, Bassett J, Bowe S, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith R, Spry N, Stockler M, Syme R, Tai K, Turner S. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun; 17(6):727-37. | C | Lancet Oncology |
| 01/05/2016 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, House MJ, Kennedy A, Joseph DJ, Denham JW. Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: A comparison of conventional and machine-learning methods. Med Phys. 2016 May; 43(5):2040 | A | Medical Physics |
| 01/04/2016 | 8.03 | RAVES | Genitourinary | Tesson S, Sundaresan P, Ager B, Butow P, Kneebone A, Costa D, Woo H, Pearse M, Juraskova, Turner S. Knowledge, attitudes and decision-making preferences of men considering participation in the TROG RAVES Prostate Cancer Trial (TROG 08.03). Radiother Oncol.2016 Apr; 119(1):84-90. | A | Radiotherapy and Oncology |
| 01/03/2016 | 1.04 | - | Gastrointestinal | McLachlan S, Fisher R, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland S, McKendrick J, McClure B, Mackay J, Ngan S. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar; 55:15-26. | A | European Journal of Cancer |
| 01/02/2016 | 3.06 | TOAD | Genitourinary | Duchesne G, Haworth A, Bone E, Carter H, Ebert M, Gagliardi F, Gibbs A, Hornby C, Martin A, Sidhom M, Wood M, Jackson M. Testing the Assessment of New Radiation Oncology Technologyand Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques. J Med Imag Radiat Oncol. 2016 Feb; 60(1):129-37. | C | Journal of Medical Imaging and Radiation Oncology |
| 01/12/2015 | 8.03 | RAVES | Genitourinary | Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, Wiltshire K, Haworth K, Fraser-Browne C, Martin J. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. Int J Radiat Oncol Biol Phys. 2015 Dec; 93(5):1045-51. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2015 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert M, Bulsara M, House M, Kennedy A, Joseph D, Denham J. Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models. Radiother Oncol. 2015 Nov; 117(2):277-82 | A | Radiotherapy and Oncology |
| 01/10/2015 | 3.04 | RADAR | Genitourinary | Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW. Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data. Pathology. 2015 Oct; 47(6):520–25. | A | Pathology |
| 01/10/2015 | 12.03 | EAT | Head and Neck | Beck A, Baker A, Britton B, Wratten C, Bauer J, Wolfenden L, Carter G. Fidelity considerations in translational research: Eating As Treatment - a stepped wedge, randomised controlled trial of a dietitian delivered behaviour change counselling intervention for head and neck cancer patients undergoing radiotherapy. TRIALS. 2015 Oct; 16:465. | C | Trials |
| 01/09/2015 | 2.01 | - | Skin | Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers MB, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry B, Babington S, Duprat J, Hoekstra H, Thompson J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep; 16(9):1049-60. | A | Lancet Oncology |
| 01/07/2015 | 12.03 | EAT | Head and Neck | Britton B, McCarter K, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McElduff P, Halpin S, Carter G. Eating As Treatment (EAT) study protocol: a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy. BMJ Open. 2015 Jul; 5(7):e008921. | C | BMJ Open |
| 01/07/2015 | 3.05 | MA.20 | Breast | Whelan T.J, Olivotto I, Parulekar W, Ackerman I, Chua B, Nabid A, Vallis K, White J, Rousseau P, Fortin A, Pierce L, Manchul L, Chafe S, Nolan M, Craighead P, Bowen J, McCready D, Pritchard K, Gelmon K, Murray Y, Chapman J, Chen B, Levine, M. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015 Jul; 373(4):307-16. | B | New England Journal of Medicine |
| 01/07/2015 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW. Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol. 2015 July; 116(1):112-8, | A | Radiotherapy and Oncology |
| 01/06/2015 | 11. A | ANROTAT | NA | Duchesne G, Grand M, Kron T, Haworth A, Corry J, Jackson M, Burmeister B. (2014). Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. J Med Imag Radiat Oncol. 2015 Jun; 59(3):363-70. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/06/2015 | 11. A | ANROTAT | NA | Brown E, Cray A, Haworth A, Chander S, Lin R, Subramanian B, Ng M. Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Rad Sci. 2015 Jun; 62(2):99-107. | A | Journal of Medical Radiation Sciences |
| 01/06/2015 | 3.04 | RADAR | Genitourinary | Denham J, Steigler A , Joseph D, Lamb D, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna N, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday E, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol. 2015 Jun; 115(3):301-07. | A | Radiotherapy and Oncology |
| 01/05/2015 | 8.05 | WBRT | Skin | Fogarty G, Hong A, Dolven-Jacobsen K, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson J. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes. 2015 May; 8(192). | C | BMC Research notes |
| 01/04/2015 | 10.02 | RAPID | Breast | Peterson DJ, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim D-H, Kong I, Germain I, Nichol A, Akra M, Roy I, Reed M, Fyles A, Trotter T, Perera F, Balkwill S, Lavertu S, Elliott E, Julian JA, Levine MN, Whelan TJ. Predictors of adverse cosmetic outcome in the RAPID trial: An exploratory analysis. Int J Radiat Oncol Biol Phys. 2015 Apr; 91(5):968-76. | B | International Journal of Radiation Oncology Biology Physics |
| 01/03/2015 | 3.04 | RADAR | Genitourinary | Ebert M, Foo K, Haworth A, Gulliford S, Kennedy A, Joseph D, Denham J. Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: analysis of data from the RADAR prostate radiation therapy trial. Int J Radiat Oncol Biol Phys. 2015 Mar; 91(3):595-603. | A | International Journal of Radiation Oncology Biology Physics |
| 01/02/2015 | 3.04 | RADAR | Genitourinary | Ebert M, Bulsara M, Haworth A, Kearvell R, Richardson S, Kennedy A, Spry N, Bydder S, Joseph D, Denham J. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates? J Med Imag Radiat Oncol. 2015 Feb; 59(1):99-108. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/12/2014 | 3.04 | RADAR | Genitourinary | Elsner K, Francis K, Hruby G, & Roderick S. Quality improvement process to assess tattoo alignment, set-up accuracy and isocentre reproducibility in pelvic radiotherapy patients. J Med Radiat Sci. 2014 Dec; 61(4):246-52. | A | Journal of Medical Radiation Sciences |
| 01/09/2014 | 3.04 | RADAR | Genitourinary | Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014 Sep; 15(10):1076-89. | A | Lancet Oncology |
| 01/09/2014 | 3.04 | RADAR | Genitourinary | Denham J, Nowitz M, Joseph D, Duschesne G, Spry N, Lamb D, Matthews J, Turner S, Atkinson C, Tai K-H, Gogna K, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, D’Este C, McElduff P, Steigler A, Kautto A, Ball J. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the TROG 03.04 RADAR trial for locally advanced prostate cancer. BJU Int. 2014 Sep; 114(3):344-53. | A | BJU International |
| 01/08/2014 | 11. A | ANROTAT | NA | Carter H, Martin A, Schofield D, Duchesne G, Haworth A, Hornby C, Sidhom M, Jackson M. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiother Oncol. 2014 Aug; 112(2):187-93. | A | Radiotherapy and Oncology |
| 01/07/2014 | - | - | NA | Christie D, Sharpley C. The successful contribution by the Trans-Tasman Radiation Oncology Group to intergroup radiation oncology trials (2010-2012) and a proposal for accrual definitions. Radiother Oncol. 2014 Jul; 112(1):153-54. | NA | Radiotherapy and Oncology |
| 01/06/2014 | 8.03 | RAVES | Genitourinary | Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early Lessons from the 08.03 RAVES Trial. J Clin Oncol. 2014 Jun; 26(6):348-52. | A | Journal of Clincal Oncology |
| 01/05/2014 | 3.04 | RADAR | Genitourinary | Galvao DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb D, Chambers S, Newton R. A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAR. Eur Urol. 2014 May; 65(5):856-64. | A | European Urology |
| 01/05/2014 | 3.04 | RADAR | Genitourinary | Sharpley CF, Bitsika V, Denham JW. Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial. Psycho-Oncology 2014 May; 23(5):524-30. | A | Psycho Oncology |
| 01/05/2014 | 10.01 | BOLART | Genitourinary | Foroudi F, Pham D, Rolfo A, Bressel M, Tang C, Tan A, Turner S, Hruby G, Williams S, Hayne D, Lehman M, Skala M, Jose C, Gogna K, Kron T. The outcome of a multi-centre feasibility study of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer TROG 10.01 BOLART. Radiother Oncol. 2014 May; 111(2):316-20. | A | Radiotherapy and Oncology |
| 01/04/2014 | 3.04 | RADAR | Genitourinary | Chang D, Joseph DJ, Ebert MA, Galvao DA, Taaffe DR, Denham JW, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imag Radiat Oncol. 2014 Apr; 58(2):223-28. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/03/2014 | 9.02 | CHISEL | Lung | Hardcastle N, Clements N, Chesson B, Aarons Y, Cramb J, Siva S, Wanigaratne DM, Ball D, Kron T. Results of patient specific quality assurance for patients undergoing stereotactic ablative radiotherapy for lung lesions. Australas Phys Eng Sci Med. 2014 Mar; 37(1):45-52. | A | Australasian Physical and Enginerring Sciences in Medicine |
| 01/03/2014 | 7.03 | DCIS | Head and Neck | Macann A, Fua T, Milross C, Porceddu S, Penniment M, Wratten C, Krawitz H, Poulsen M, Tang CI, Morton RP, Hay KD, Thomson V, Bell ML, King MT, Fraser-Browne CL, Hockey HP. Phase III trial of domiciliary humidification to mitigate acute mucosal toxicity during radiotherapy for head and neck cancer: First report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study. Int J Radiat Oncol Biol Phys. 2014 Mar; 88(3):572-79 | A | International Journal of Radiation Oncology Biology Physics |
| 01/03/2014 | 8.03 | RAVES | Genitourinary | Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the RAVES trial (Radiotherapy Adjuvant Versus Early Salvage). BJU Int. 2014 Mar; 113(S2):7-12. | A | BJU International |
| 01/02/2014 | 3.08 | - | Symptom Management | Chow E, van der Linden Y, Roos DE, Hartsell WF, Hoskin P, Wu Jackson S, Brundage M, Nabid A, Tissing-Tan C, Oei B, Babington S, Demas W, Wilson F, Meyer R, Chen B, Wong R. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014 Feb; 15(2):164-71. | B | Lancet Oncology |
| 01/01/2014 | TROG | - | NA | Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O’Sullivan B, Porceddu S, Lengele B. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014 Jan; 110(1):172-81. | NA | Radiotherapy and Oncology |
| 01/11/2013 | 10.02 | RAPID | Breast | Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. J Clin Oncol. 2013 Nov; 31(32):4038-45. | B | Journal of Clincal Oncology |
| 01/11/2013 | 6.02 | APBI | Breast | Kron T, Willis D, Link E, Lehman M, Campbell G, O’Brien P and Chua B. Can we predict plan quality for external beam partial breast irradiation: Results of a multicenter feasibility study (Trans Tasman Radiation Oncology Group Study 06.02). Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):817-824. | A | International Journal of Radiation Oncology Biology Physics |
| 01/10/2013 | 10.01 | BOLART | Genitourinary | Foroudi F, Pham D, Bressel M, Tongs D, Rolfo A, styles C, Gill S, Kron T. The utility of e-Learning to support training for a multicentre bladder online adaptive radiotherapy trial (TROG 10.01-BOLART). Radiother Oncol. 2013 Oct; 109(1):165-69. | A | Radiotherapy and Oncology |
| 01/09/2013 | 99.05 | - | Lung | Ball D, Fisher R, McClure B. Response to Dahele and Senan. Radiother Oncol.12 October 2013;109 (1):180-181.(Refers to Max Dahele, Suresh Senan. What causes early mortality in patients with large tumors receiving radical chemo-radiotherapy for non-small cell lung cancer? In response to Ball et al. Radiother Oncol. 2013 Sep; 109: 178-82. | A | Radiotherapy and Oncology |
| 01/08/2013 | TROG | - | NA | Christie D. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012. J Med Imag Radiat Oncol. 2013 Aug; 57(4):499-502. | NA | Journal of Medical Imaging and Radiation Oncology |
| 01/07/2013 | 8.01 | PROFIT | Genitourinary | Healy B, Frantzis J, Murry R, Martin J, Plank A, Middleton M, Catton C, Kron T. Results from a multicentre prostate IMRT dosimetry intercomparison for an OCOG-TROG clinical trial. Med Phys. 2013 Jul; 40(7):071706. | B | Medical Physics |
| 01/06/2013 | 8.01 | PROFIT | Genitourinary | Martin J, Frantzis J, Chung P, Langah I, Crain M, Cornes D, Plank A, Finch T, Jones M, Khoo E, Catton C. Prostate Radiotherapy Clinical Trial Quality Assurance: How Real Should Real Time Review Be? (A TROG-OCOG Intergroup Project). Radiother Oncol. 2013 Jun; 107(3):333-38. | B | Radiotherapy and Oncology |
| 01/05/2013 | 9.03 | MP3 | Skin | Finnigan R, Hruby G, Wratten C, Keller J, Tripcony L, Dickie G, Rischin D, Poulsen M. The impact of pre-radiation residual disease volume on time to locoregional failure in cutaneous merkel cell carcinoma – A TROG substudy. Int J Radiat Oncol Biol Phys. 2013 May; 86(1):91-5. | A | International Journal of Radiation Oncology Biology Physics |
| 01/05/2013 | 4.01 | - | Symptom Management | Graham PH, Plant N, Browne L, Borg M, Capp A, Delaney G, Harvey J, Kenny L, Francis M, Zissiadis Y. A paired double blind randomised comparison of a moisturising durable barrier cream (MDBC) to 10% glycerine ("Sorbolene") cream in the prophylactic management of post-mastectomy irradiation skin care. Trans Tasman Radiation Oncology Group (TROG) 04.01. Int J Radiat Oncol Biol Phys. 2013 May; 86(1):45-50. | A | International Journal of Radiation Oncology Biology Physics |
| 01/05/2013 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Tai K-H, Joseph D, Matthews J, Atkinson C, Spry NA, Turner S, North J, Christie C, Wynne C, Lamb DS. Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiother Oncol. 2013 May; 107(2):123-28. | A | Radiotherapy and Oncology |
| 01/04/2013 | 3.04 | RADAR | Genitourinary | Geraghty JP, Grogan G, Ebert MA. Automatic segmentation of male pelvic anatomy on computed tomography images: a comparison with multiple observers in the context of a multicentre clinical trial. Radiat Oncol. 2013 Apr; 8:106 | A | Radiotherapy and Oncology |
| 01/04/2013 | 3.04 | RADAR | Genitourinary | Kearvell R, Haworth A, Ebert MA, Murray J, Hooton B, Richardson S, Joseph DJ, Lamb D, Spry NA, Duchesne G, Denham JW. Quality improvements in prostate radiotherapy: Outcomes and impacts of comprehensive quality assurance during the TROG 03.04 ‘RADAR’ trial. J Med Imag Radiat Oncol. 2013 Apr; 57(2):247–57. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/04/2013 | 10.01 | BOLART | Genitourinary | Pham D, Roxby P, Kron T, Rolfo A, Foroudi F. Introduction of Online Adaptive Radiotherapy for Bladder Cancer through a Multicentre Clinical Trial (TROG 10.01): Lessons Learned. Jour Med Phys. 2013 Apr; 38(2):59-66. | A | Journal of Medical Physics |
| 01/03/2013 | 99.05 | - | Lung | Ball D, Fisher R, Burmeister B, Poulsen M, Graham P, Penniment M, Vinod S, Krawitz H, Joseph D, Wheeler G, McClure B. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol. 2013 Mar; 106(3):305-11. | A | Radiotherapy and Oncology |
| 01/03/2013 | 2.02 | Head and Neck | Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T. Radiotherapy Protocol Deviations and Clinical Oucomes: A Meta-Analysis of Cooperative Group Clinical Trials. J Natl Cancer Inst. 2013 Mar; 105(6):387-93. | A | Journal of the National Cancer Institute | |
| 01/02/2013 | 9.02 | CHISEL | Lung | Clements N, Kron T, Franich R, Dunn L, Roxby P, Aarons Y, Siva S, Chesson B, Duplan D, Ball D. The effect of irregular breathing patterns on internal target volumes in four-dimensional CT and cone-beam CT images in the context of stereotactic lung radiotherapy. Med Phys. 2013 Feb; 40(2):021904. | A | Medical Physics |
| 01/01/2013 | 8.09 | RTN2 | Skin | Foote M. TROG 08.09 ANZMTG 01.09. An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. J Dtsch Dermatol Ges. 2013; 11:57-58. | C | Journal of the German Society of Dermatology |
| 01/12/2012 | 3.04 | RADAR | Genitourinary | Denham JW, Wilcox C, Joseph D, Spry N, Lamb D, Tai K-H, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012 Dec; 13(12):1260-70. | A | Lancet Oncology |
| 01/12/2012 | 96.01 | - | Genitourinary | Steigler, Allison, James W. Denham, David S. Lamb, Nigel A. Spry, David Joseph, John Matthews, Chris Atkinson, Turner S, North J, Christie D, Tai K-H, Wynne C. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial. Prostate Cancer. 2012 Dec; 2012:814724. | A | Prostate Cancer |
| 01/12/2012 | 9.02 | CHISEL | Lung | Siva S, Shaw M, Chesson B, Gill S and Ball D. Analysis of the impact of chest wall constraints on eligibility for a randomized trial of stereotactic body radiotherapy of peripheral stage I non-small cell lung cancer. J Med Imag Radiat Oncol. 2012 Dec; 56(6):654-60. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/11/2012 | 1.04 | - | Gastrointestinal | Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D, Ackland S, Schache D, McClure B, McLachlan S, McKendrick J, Leong T, Hartopeanu C, Zalcberg and Mackay J. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer (TROG01.04). J Clin Oncol. 2012 Nov; 30(31):3827-33. | A | Journal of Clinical Oncology |
| 01/11/2012 | 3.04 | RADAR | Genitourinary | Denham JW, Wilcox C, Lamb D, Spry N, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna NK, Ebert M, Delahunt B, McElduff P, Joseph D. Rectal and Urinary Dysfunction in the TROG 03.04 RADAR Trial for Locally Advanced Prostate Cancer. Radiother Oncol. 2012 Nov; 105(2):184-92. | A | Radiotherapy and Oncology |
| 01/08/2012 | 2.02 | - | Head and Neck | Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol. 2012 Aug; 48(8):689-702. | A | Oral Oncology |
| 01/08/2012 | 4.01 | - | Symptom Management | Graham P, Plant N, Graham J, Browne L, Martin Borg M, Capp A, Delaney, Harvey J, Kenny L, Francis M, Zissiadis Y. Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. J Med Imag Radiat Oncol. 2012 Aug; 56(4):458-63. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/06/2012 | 2.01 | - | Skin | Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Kerwin S, Scolyer RA, Curruthjers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012 Jun; 13(6):589-97. | A | Lancet Oncology |
| 01/06/2012 | 10.01 | BOLART | Genitourinary | Kron T, Pham D, Roxby P, Rolfo A, Foroudi F. Credentialing of radiotherapy centres for a clinical trial of adaptive radiotherapy for bladder cancer (TROG 10.01). Radiother Oncol, 2012 Jun; 103(3):293-98. | A | Radiotherapy and Oncology |
| 01/06/2012 | 2.02 | - | Head and Neck | Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O’Sullivan B, Giacia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without Tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 2012 Jun; 18(6):1798-807. | A | Clinical Cancer Research |
| 01/06/2012 | 6.01 | LGG | Central Nervous System | Fairchild A, Weber DC, Bar-Deroma R, Gulyban A, Fenton PA, Stupp R, Baumert BG. Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. Radiother Oncol. 2012 Jun;103(3):287-92. doi: 10.1016/j.radonc.2012.04.002. Epub 2012 May 3. PMID: 22560713. | B | Radiotherapy and Oncology |
| 01/02/2012 | 96.01 | - | Genitourinary | D’Amico AV, Chen M-H, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW and Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012 Feb; 13 (2) 189-95. | A | Lancet Oncology |
| 01/02/2012 | TROG | - | NA | Grand M, O’Brien P. Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature. J Med Imag Radiat Oncol. 2012 Feb; 56(1):31-9. | NA | Journal of Medical Imaging and Radiation Oncology |
| 01/02/2012 | 3.04 | RADAR | Genitourinary | Wilcox C, Kautto A, Steigler A, Denham J. Androgen Deprivation Therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncol. 2012 Feb; 82(1):56-8. | A | Oncology |
| 01/01/2012 | 2.02 | - | Head and Neck | Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Prognostic significance of Plasma Osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012 Jan; 18(1):301-07. | A | Clinical Cancer Research |
| 01/12/2011 | 8.01 | PROFIT | Genitourinary | Middleton M, Frantzis J, Healy B, Jones M, Murry R, Kron T, Plank A, Catton C, Martin J. Successful Implementation of Image Guided radiation therapy Quality Assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. Int J Rad Onc Biol Phys. 2011 Dec; 81(5):1576-81. | B | International Journal of Radiation Oncology Biology Physics |
| 01/12/2011 | 3.07 | - | Lung | Burmeister BH, Michael M, Burmeister E, Cox S, Lehman M, Wirth A, Horwood K, Sasso G, Forouzesh B, Ball D. A randomised phase II trial of 2 regimens of moderate dose chemoradiation therapy for patients with non small cell lung cancer not suitable for curative therapy - Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 2011 Dec; 6(12):2076-82. | A | Journal of Thoracic Oncology |
| 01/12/2011 | 8.03 | RAVES | Genitourinary | Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol. 2011 Dec; 101(3):521-524. | A | Radiotherapy and Oncology |
| 01/12/2011 | 96.01 | - | Genitourinary | D’Amico AV, Chen M-H, Crook J, Armstrong JG, Malone S, Steigler A, Dunne M, Kantoff PW, and Denham JW. Duration of short course androgen suppression therapy and the risk of death from prostate cancer. J Clin Oncol. 2011 Dec; 29(35):4682-87. | A | Journal of Clinical Oncology |
| 01/12/2011 | 96.01 | - | Genitourinary | Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A and D’Este C. Another form of subgroup to beware. (Letter to the Editor). Radiother Oncol. 2011 Dec; 101(3): 525-526. | A | Radiotherapy and Oncology |
| 01/10/2011 | 3.04 | RADAR | Genitourinary | Harrison KM, Ebert MA, Kron T, Howlett SJ, Cornes D, Hamilton CS, Denham JW. Design, manufacture and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison. Med Phys. 2011 Oct; 38(10):5330-37. | A | Medical Physics |
| 01/09/2011 | 96.07 | - | Skin | Poulsen M, Rischin D, Walpole E, Harvey J, Macintosh J, Ainslie J, Hamilton C, Keller J Tripcony L. Analysis of toxicity of Merkel Cell Carcinoma of the skin treated with synchronous carboplatin/etopside and radiation: A Trans-Tasman Radiation Oncology Group study - TROG 96. 07. Int J Radiat Oncol Biol Phys. 2001 Sep; 51(1):156-63. | A | International Journal of Radiation Oncology Biology Physics |
| 01/09/2011 | 3.04 | RADAR | Genitourinary | Ebert MA, Harrison KM, Howlett SJ, Cornes D, Bulsara M, Hamilton CS, Kron T, Joseph DJ, Denham JW. Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom. Med Phys. 2011 Sep; 38(9):5167-75. | A | Medical Physics |
| 01/07/2011 | 99.04 | - | Lymphoma | Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited Chemotherapy and Shrinking Field radiotherapy for Osteolymphoma (primary bone lymphoma): Results from the Trans Tasman radiation Oncology Group 99.04 and Australasian Leukemia and Lymphoma Group LY02 Prospective Trial. Int J Radiat Oncol Biol Phys. 2011 Jul; 80(4):1164-70. | A | International Journal of Radiation Oncology Biology Physics |
| 01/06/2011 | 8.01 | PROFIT | Genitourinary | Healy B, Frantzis J, Murry R, Martin J, Middleton M, Catton C, Kron T. Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer. Australas Phys Eng Sci Med. 2011 Jun; 34(2):195-202. | B | Australasian Physical and Enginerring Sciences in Medicine |
| 01/06/2011 | 2.02 | - | Head and Neck | Young R, Rischin D; Fisher R; et al. Relationship between Epidermal Growth Factor Receptor Status, p16(INK4A), and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Biomar Prev. 2011 Jun; 20(6):1230-37. | A | Cancer Epidemiology Biomarkers and Prevention |
| 01/05/2011 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie C, Spry NA, Tai K-H, Wynne C, D’Este C. Short term neoadjuvant androgendeprivation and radiotherapy for locally advanced prostate cancer: 10 year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May; 12(5):451-59. | A | Lancet Oncology |
| 01/03/2011 | 3.02 | - | Gastrointestinal | Leong T, Lim Joon D, Willis D, Jayamoham J, Spry N, Harvey J, Di lulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-fluorouracil before and after three-dimensional Conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation Oncology group. Int J Radiat Oncol Biol Phys. 2011 Mar; 79(3):690-95. | A | International Journal of Radiation Oncology Biology Physics |
| 01/02/2011 | 96.01 | - | Genitourinary | Lamb DS, Denham JW, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A, Delahunt B, D’Este C. A comparison of the prognostic value of early PSA based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys. 2011 Feb; 79(2);385-391. | A | International Journal of Radiation Oncology Biology Physics |
| 01/01/2011 | 99.01 | - | Lymphoma | Wirth A, Grigg A, Wolf M, Goldstein D, Johnson C, Davis S, Dutu G, Kypreos P, Smith C, Kneebone A, Herzberg M, Joseph D, Catalano J, Roos D, Reynolds J. Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma. 2011; 52(5):786–95. | A | Leukemia and Lymphoma |
| 01/01/2011 | 9.02 | CHISEL | Lung | Kron T, Clements N, Aarons Y, Dunn L, Cheeson B, Miller J, Roozen K, Ball D. Radiochromic film for individual patient QA in extracranial stereotacic lung radiotherapy. Radiat Meas. 2011; 46:1920-23. | A | Radiation Measurements |
| 01/01/2011 | 99.02 | - | Gastrointestinal | Matthews J, Burmeister B, Borg M, Capp A, Joseph D, Thompson KM, Thompson PI, Harvey JA, Spry NA. T1-2 anal carcinoma requires elective inguinal radiation treatment- the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol. 2011 Jan; 98(1):93-98. | A | Radiotherapy and Oncology |
| 01/10/2010 | 3.08 | - | Symptom Management | Roos D. Response to “Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Results from three Canadian centers”. Int J Rad Onc Biol Phys. 2010 Oct; 78(2):637. | B | International Journal of Radiation Oncology Biology Physics |
| 01/10/2010 | 3.06 | TOAD | Genitourinary | Duchesne GM, Woo HH, Howell D, Kaimakamis M, Kemp E. Tribulations of a prostate cancer trial – lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. J Med Imag Radiat Oncol. 2010 Oct; 54(5):508-11. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/09/2010 | 2.02 | - | Head and Neck | Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA. Prognostic Significance of p16INK4A and Human Papillomavirus in patients with Oropharyngeal Cancer Treated on TROG 02.02 Phase III trial. J Clin Oncol. 2010 Sep; 28(27):4142-48. | A | Journal of Clinical Oncology |
| 01/06/2010 | 2.02 | - | Head and Neck | Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun; 28(18):2989-95. | A | Journal of Clinical Oncology |
| 01/06/2010 | 2.02 | - | Head and Neck | Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. J Clin Oncol. 2010 Jun; 28(18):2996-3001. | A | Journal of Clinical Oncology |
| 01/06/2010 | 3.04 | RADAR | Genitourinary | Delahunt B, Lamb DS, Srigley JR, et al. Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point. Pathology. 2010 Jun; 42(4):339-43. | A | Pathology |
| 01/06/2010 | 3.04 | RADAR | Genitourinary | Ebert MA, Haworth A, Kearvell R, Hooton B, Hug B, Spry NA, Bydder SA, Joseph DJ. Comparison of DVH data from multiple radiotherapy treatment planning systems. Phys Med Biol. 2010 Jun; 55(11):N337-46. | A | Physics in Medicine and Biology |
| 01/05/2010 | 6.01 | LGG | Central Nervous System | Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, Collette L, Stupp R, Weber DC, Bernard Davis J, Aird E, Baumert BG. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. Radiother Oncol. 2010 May;95(2):218-24. doi: 10.1016/j.radonc.2010.03.005. Epub 2010 Apr 6. PMID: 20378192. | B | Radiotherapy and Oncology |
| 01/01/2010 | 9.02 | CHISEL | Lung | Clements N, Kron T, Dunn L, Aarons Y, Cheeson B, Miller J, Ball D. Patient-specific QA for motion management in hypofractionated lung radiotherapy. Med Phys. 2010; 37: 3420. | A | Medical Physics |
| 01/12/2009 | 3.04 | RADAR | Genitourinary | Galvao DA, Spry N, Taaffe DR, Denham J; Joseph D; Lamb DS; Levin G ; Duchesne, G, Newton RU.A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer. 2009 Dec; 9: 419. | A | BMC Cancer |
| 01/11/2009 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Kumar M, Lamb DS, Spry NA, Tai K, Atkinson C, Turner S, Greer PG, Gleeson PS, D’Este C. Measuring time to Biochemical Failure in the TROG 96.01 Trial: When should the clock start ticking? Int J Radiat Oncol Biol Phys. 2009 Nov; 75 (4):1008-12. | A | International Journal of Radiation Oncology Biology Physics |
| 01/10/2009 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Tai K-H, Spry NA, Gleeson PS, D’Este C. Why are pretreatment PSA levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer. 2009 Oct; 115(19):4477-87. | A | Cancer |
| 01/08/2009 | 6.02 | APBI | Breast | Kron T, Willis D, Bignell F, Martland J, Donnell S, May S, Chua BH. Centre credentialing for Trans Tasman Radiation Oncology Group trial 06.02: multicentre feasibility study of accelerated partial breast irradiation. J Med Imag Radiat Oncol. 2009 Aug; 53(4):412–18. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/06/2009 | 6.02 | APBI | Breast | Kron T, Willis D, Miller J, Hubbard P, Oliver M, Chua B. A spreadsheet to determine the volume ratio for target and breast in partial breast irradiation. Australas Phys Eng Sci Med. 2009 Jun; 32(2):98-104. | A | Australasian Physical and Enginerring Sciences in Medicine |
| 01/06/2009 | 96.01 | - | Genitourinary | Denham JW, Kumar M, Gleeson PS, , Lamb DS; Joseph D; Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Turner S, Greer PB, D'Este C, Steigler A. Recognising false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun; 74(2):404-11. | A | International Journal of Radiation Oncology Biology Physics |
| 01/04/2009 | 99.04 | - | Lymphoma | Christie D, Le T, Watling K, Cornes D, O’Brien P, Hitchins R. Quality assurance audit: A prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). J Med Imag Radiat Oncol. 2009 Apr; 53(2):203–06. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/03/2009 | 3.04 | RADAR | Genitourinary | Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, Duchesne G, Murray J, Joseph D. Assuring high quality treatment delivery in clinical trials – Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 “RADAR” set-up accuracy study. Radiother Oncol. 2009 Mar; 90(3):299-306. | A | Radiotherapy and Oncology |
| 01/03/2009 | 96.01 | - | Genitourinary | Capp A, Inostroza-Ponta M, Bill D, Moscato P, Lai C, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North J, Poulsen M, Spry N, Tai KH, ; Wynne C, Duchesne G, Steigler A, Denham JW. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol. 2009 Mar; 90(3):400-07. | A | Radiotherapy and Oncology |
| 01/03/2009 | 96.01 | - | Genitourinary | Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry, NA, Duchesne G, Ebert M, Steigler A, D'Este C. PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol. 2009 Mar; 90(3):382-88. | A | Radiotherapy and Oncology |
| 01/02/2009 | 3.04 | RADAR | Genitourinary | Ebert MA, Harrison K, Cornes D, Howlett SJ, Joseph DJ, Kron T, Hamilton CS, Denham JW. Comprehensive Australasian multicentre dosimetric intercomparison: Issues, logistics and recommendations. J Med Imag Radiat Oncol. 2009 Feb; 53(1):119-13. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/12/2008 | 3.04 | RADAR | Genitourinary | Ebert MA, Howlett SJ, Harrison K, Cornes D, Hamilton CS, Denham JD. Linear-accelerator X-ray output: a multicentre chamber-based intercomparison study in Australia and New Zealand. Australas Phys Eng Sci Med. 2008 Dec; 31(4):255-66. | A | Australasian Radiology |
| 01/11/2008 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Wilcox C, Lamb D, Joseph D, Atkinson C, Matthews J, Tai K, Spry N, Christie D, Gleeson P, Greer PB, D'Este C, on behalf of the Trans-Tasman Radiation Oncology Group 96.01 Trialists. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008 Nov; 9(11):1058–68. | A | Lancet Oncology |
| 01/06/2008 | 98.02 | - | Head and Neck | Corry J, Peters L, Fisher R, Macann A, Jackson M, McClure B, Rischin D. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02. Head Neck. 2008 Jun; 30(6):737-42. | A | Head and Neck (Otolaryngology–Head and Neck Surgery) |
| 01/10/2007 | 99.04 | - | Lymphoma | Christie DR, Gabriel GS and Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J. 2007 Oct; 37(10):680-86. | A | Internal Medicine Journal |
| 01/06/2007 | 96.01 | - | Genitourinary | D’Amico A, Denham J, Crook J, Chen M-H, Goldhaber S, Lamb D, Joseph D, Keen-Hun T, Malone S, Ludgate C, Steigler A, Kantoff P. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun; 25(17):2420-25. | A | Journal of Clinical Oncology |
| 01/05/2007 | 96.01 | - | Genitourinary | D’Amico A, Denham J, Bolla M, Collette L, Lamb D, Thai K-H, Steigler A, Chen M-H. Short versus long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node negative high-risk adenocarcinoma of the prostate. Cancer. 2007 May; 109(10):2004-10. | A | Cancer |
| 01/11/2006 | 96.06 | - | Skin | Burmeister B. Smithers M, Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C and Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol. 2006 Nov; 81(2):136–42. | A | Radiotherapy and Oncology |
| 01/10/2006 | 99.06 + 97.01 | - | Genitourinary/Gastrointestinal | Gogna N, Matthews J, Turner S, Mameghan H, Duchesne G, Spry N, Berry M, Keller J and Tripcony L. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006 Oct; 81(1):9–17. | A | Radiotherapy and Oncology |
| 01/09/2006 | 99.05 | - | Lung | Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, Krawitz H, Wheeler G, Poulsen M, Vinod S and McClure B. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006 Sep; 1(7):667-72. | A | Journal of Thoracic Oncology |
| 01/09/2006 | 98.05 | - | Central Nervous System | Roos D, Wirth A, Burmeister B, Spry N, Drummond K, Beresford J and McClure B. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol. 2006 Sep; 80(3):318-22. | A | Radiotherapy and Oncology |
| 01/06/2006 | 3.06 | TOAD | Genitourinary | Duchesne, GM, Syme R, Howell D. How early is early: Androgen deprivation for prostate-specific antigen relapse in prostate cancer. J Clin Oncol. 2006 June; 24(18):2964-64. | A | Journal of Clinical Oncology |
| 01/05/2006 | 98.02 | - | Head and Neck | Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S and Peters LJ. Prognostic significance of [F-18]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol. 2006 May; 24(13):2098-04. | A | Journal of Clinical Oncology |
| 01/04/2006 | - | - | NA | Chen Y, Trotti A, Coleman CN, Machtay M, Mirimanoff RO, Hay J, O’Brien PC, El-Gueddari B, Salvajoli JV, Jeremic B. Adverse Event Reporting And Developments In Radiation Biology After Normal Tissue Injury: International Atomic Energy Agency Consultation. Int J Radiat Oncol Biol Phys. 2006 Apr; 64(5):1442–51. | NA | International Journal of Radiation Oncology Biology Physics |
| 01/03/2006 | 3.08 | - | Symptom Management | Chow E, Hoskin P, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. J Clin Oncol. 2006 Mar; 18 (2):125-128. (Editorial) | B | Journal of Clinical Oncology |
| 01/02/2006 | 1.05 | - | Symptom Management | Graham PH, Capp A, Delaney G, Goozee G, Hickey B, Turner S, Browne L, Milross C, Wirth A. A pilot randomised comparison of Dexamethasone 96 mg versus 16mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex Study. J Clin Oncol. 2006 Feb; 18(1):70-6. | A | Journal of Clinical Oncology |
| 01/02/2006 | 92.01 | - | Lymphoma | O’Brien PC, Roos DE, Pratt G, Liew K-H, Barton MB, Poulsen MG, Olver IA, Trotter GE. Combined-modality Therapy for Primary Central Nervous System Lymphoma: Long-term Data from a Phase II Multi-center Study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006 Feb; 64(2):408-13. | A | International Journal of Radiation Oncology Biology Physics |
| 01/01/2006 | 96.07 | - | Skin | Poulsen M, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L. Does Chemotherapy improve survival in high risk stage I and II Merkel Cell Carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006 Jan; 64(1):114-19. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2005 | 96.01 | - | Genitourinary | Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry N, Tai K, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D’Este C, Bill D. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol. 2005 Nov; 77(2):117-25. | A | Radiotherapy and Oncology |
| 01/09/2005 | 94.01 | - | Gastrointestinal | Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep; 6(9):659-68. | A | Lancet Oncology |
| 01/07/2005 | 98.01 | - | Gastrointestinal | Ngan SYK, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D. Promising results of a co-operative group phase II trials of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum. 2005 Jul; 48(7):1389-96. | A | Diseases of the Colon and Rectum |
| 01/04/2005 | 96.05 | - | Symptom Management | Roos D, Turner S, O'Brien P, Smith J, Spry N, Burmeister B, Hoskin P, Ball D. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr; 75(1):54-63. | A | Radiotherapy and Oncology |
| 01/03/2005 | 96.05 | - | Symptom Management | Pollicino CA, Turner SL, Roos DE, O’Brien PC. Costing the components of pain management. Analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): One versus five fractions for neuropathic bone pain. Radiother Oncol. 2005 Sep; 76(3):264–69. | A | Radiotherapy and Oncology |
| 01/02/2005 | - | - | NA | Christie D, Sharpley C, Curtis T. Improving the Accuracy of a Photographic Assessment System for Breast Cosmesis. J Clin Oncol. 2005 Feb; 17(1):27-31. | NA | Journal of Clinical Oncology |
| 01/01/2005 | 96.01 | - | Genitourinary | Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai K-H, Wynne C, Duchesne G, Kovacev O, D’Este C. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6(11):841-50 | A | Lancet Oncology |
| 01/01/2005 | 98.02 | - | Head and Neck | Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005 Jan; 23(1):79-87. | A | Journal of Clinical Oncology |
| 01/12/2003 | 96.07 | - | Skin | Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07. J Clin Oncol. 2003 Dec; 21(23): 4371-76. | A | Journal of Clinical Oncology |
| 01/09/2003 | 96.01 | - | Genitourinary | Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol. 2003 Sep; 68(3):255–67. | A | Radiotherapy and Oncology |
| 01/09/2003 | 98.04 | - | Symptom Management | Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, Davis S, Joseph DJ, Poulsen M, Berry M. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol. 2003 Sep; 47(3):284–88. | A | Australasian Radiology |
| 01/08/2003 | 91.01 | - | Head and Neck | Daly T, Poulsen GM, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003 Aug; 68(2): 113–22. | A | Radiotherapy and Oncology |
| 01/05/2003 | 96.02 + 89.04 | - | Gastrointestinal | Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. J Clin Oncol. 2003 May; 15(3): 98–108. | A | Journal of Clinical Oncology |
| 01/05/2003 | 96.05 | - | Symptom Management | Roos DE, Davis SR, Turner SL, O’Brien PC, Spry NA, Burmeister BH, Hoskin PJ and Ball DL. Quality assurance experience with the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiother Oncol. 2003 May; 67(2):207–12. | A | Radiotherapy and Oncology |
| 01/05/2002 | 96.06 | - | Skin | Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C Krawitz H, Baumann KC. Radiation therapy following nodal surgery for melanoma: An analysis of toxicity. ANZ J Surg. 2002 May; 72(5):344–48. | A | ANZ Journal of Surgery |
| 01/02/2002 | 96.01 & 91.01 | - | Genitourinary/Head and Neck | Kron T, Hamilton C, Roff M, Denham JW. Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. Int J Radiat Oncol Biol Phys. 2002 Feb; 52(2):566–79. | A | International Journal of Radiation Oncology Biology Physics |
| 01/02/2002 | 95.02 | - | Symptom Management | O'Brien PC, Franklin CI, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered Sucralfate, predict for late radiation proctitis. Longer-term follow-up of a Phase 3 trial – Trans-Tasman Radiation Oncology Group (TROG). Int J Radiat Oncol Biol Phys. 2002 Oct; 54(2):442–49. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2001 | 91.01 | - | Head and Neck | Denham JW and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys. 2001 Nov; 51(3): 807–19. | A | International Journal of Radiation Oncology Biology Physics |
| 01/08/2001 | 91.01 | - | Head and Neck | Poulsen M, Denham J, Peters L, Lamb D, Spry NA, Hindley A, Krawitz, H Hamilton C, Keller J, Tripcony L, Walker Q. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91.01). Radiother Oncol. 2001 Aug; 60(2):113-22. | A | Radiotherapy and Oncology |
| 01/07/2001 | 98.01 | - | Gastrointestinal | Ngan SYK, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, MacKay JR, Joseph D, Bell A and Goldstein D. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001 Jul; 50(4):883-87. | A | International Journal of Radiation Oncology Biology Physics |
| 01/08/2000 | 96.05 | - | Symptom Management | Roos DE, Davis SR, O'Brien PC, Hoskin PJ, Spry NA, Burmeister BH, Turner S and Bernshaw D. Eligibility audits for the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group Study, TROG 96. 05). Australas Radiol. 2000 Aug; 44(3):303-07. | A | Australasian Radiology |
| 01/03/2000 | 96.05 | - | Symptom Management | Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH, Turner S and Bernshaw D. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96. 05). Int J Radiat Oncol Biol Phys. 2000 Mar; 46(4): 975-81. | A | International Journal of Radiation Oncology Biology Physics |
| 01/02/2000 | 96.01 | - | Genitourinary | Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, Turner S, Spry N, Poulsen M, North J, Kovacev O and Denham J. A quality assurance audit: Phase III trial of maximal androgen deprivation in prostate cancer (TROG 96. 01). Australas Radiol. 2000 Feb; 44(1): 65-71. | A | Australasian Radiology |
| 01/02/2000 | 92.01 | - | Lymphoma | O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I and Trotter G. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000 Feb; 18(3):519-26. | A | Journal of Clinical Oncology |
| 01/11/1999 | 91.01 | - | Head and Neck | Poulsen M, Denham JW, Spry N, Lamb D, Peters L, Williamson S and L Tripcony. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Acute toxicity analysis of a phase III randomised trial of accelerated. Australas Radiol. 1999 Nov; 43(4):487-94. | A | Australasian Radiology |
| 01/06/1999 | 96.02 | - | Gastrointestinal | Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P and Spry N. Causes for increased myelosuppression with increasing age in patients with esophageal cancer treated by chemo-radiation. Eur J Cancer. 1999 Jun; 35(6):921-27. | A | European Journal of Cancer |
| 01/05/1999 | 91.01 | - | Head and Neck | Hamilton CS, Walker Q, Poulsen M, Spry N, Lamb D, Denham JW and Steigler A. Quality Assurance Audit in an Australasian Phase III Trial of Accelerated Radiotherapy for Head and Neck Cancer (TROG 91. 01). Australas Radiol. 1999 May; 43(2):227-32. | A | Australasian Radiology |
| 01/05/1999 | 91.01 | - | Head and Neck | Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O'Brien P, Spry NA, Penniment M, Krawitz H, Williamson S, Bear J, Tripcony L. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999 Aug; 52(2):157-64. | A | Radiotherapy and Oncology |
| 01/05/1999 | 89.02 | - | Breast | Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol. 1999 May; 43(2):220-26. | A | Australasian Radiology |
| 01/01/1999 | - | - | NA | Denham JW and Atkinson C. Where is your evidence? Australas Radiol. 1999; 43(1):124–25. (Editorial) | NA | Australasian Radiology |
| 01/10/1998 | 89.03 | - | Gastrointestinal | Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. | A | Radiotherapy and Oncology |
| 01/11/1997 | 95.02 | - | Symptom Management | O’Brien PC, Franklin CI, Dear KBG, Hamilton CS, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis: Trans-Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1997 Nov; 45(2):117–23. | A | Radiotherapy and Oncology |
| 01/11/1997 | 89.04 | - | Gastrointestinal | Burmeister BH, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the oesophagus: current status and future directions. Med J Aust. 1997 Oct; 167(7):349-50. | A | Medical Journal of Australia |
| 01/06/1997 | 89.04 | - | Gastrointestinal | Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg. 1997 Jun; 23(3):219-23. | A | European Journal of Surgery |
| 01/01/1997 | 89.04 | - | Gastrointestinal | Denham J and on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Response to L. R. Coia re factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1997 Jan; 42(1): 91-2. (Letter) | A | Radiotherapy and Oncology |
| 01/11/1996 | 89.03 & 91.01 | - | Head and Neck/Gastrointestinal | Denham JW, Walker QJ, Lamb DS, Hamilton CS, O'Brien PC, Spry NA et al. Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1996 Nov; 41(2):109-18. | A | Radiotherapy and Oncology |
| 01/11/1996 | 89.04 | - | Gastrointestinal | MacKean J, Burmeister BH, Lamb DS, Denham JW. Concurrent chemo-radiation for oesophageal cancer - Factors influencing myelotoxicity. Australas Radiol. 1996 Nov; 40(4):424-29. | A | Australasian Radiology |
| 01/10/1996 | 89.02 | - | Breast | Christie DRH, O'Brien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS et al. A comparison of methods of cosmetic assessment in breast conservation treatment. Breast. 1996 Oct; 5(5):358-67. | A | Breast |
| 01/10/1996 | 92.01 | - | Lymphoma | O'Brien PC, Roos D, Liew K-H, Trotter G, Barton M, Walker Q et al. Preliminary results of combined Chemotherapy and radiotherapy for non-AIDS primary Central Nervous System lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust. 1996 Oct; 165(8):424-27. | A | Medical Journal of Australia |
| 01/07/1996 | 89.04 | - | Gastrointestinal | Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1996 Jul; 40(1):31-43. | A | Radiotherapy and Oncology |
| 01/07/1995 | 89.04 | - | Gastrointestinal | Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicentre study. Int J Radiat Oncol Biol Phys. 1995 Jul; 32(4):997-1006. | A | International Journal of Radiation Oncology Biology Physics |
| 01/01/1995 | 89.02 | - | Breast | Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int J Radiat Oncol Biol Phys. 1995 Jan; 31(2): 305-13. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/1994 | NA | - | NA | Atkinson CH, Hamilton CS, Wynne CJ. Radiotherapy planning for lung cancer: Can we do better? Australas Radiol. 1994 Nov; 38(4):303-04. | NA | Australasian Radiology |
| 01/06/1994 | 89.04 | - | Gastrointestinal | Denham JW. Oesophageal cancer - guarded optimism. Med J Aust. 1994 Jun; 160(11):669-70. | A | Medical Journal of Australia |
| 01/02/1993 | NA | - | NA | Denham JW, Hamilton CS, Joseph DJ, et al. The use of simulator and CT information in the planning of radiotherapy for non-small cell lung carcinoma; an Australasian pattern of practice study. Lung Cancer. 1993 Feb; 8(5-6):275-84. | NA | Lung Cancer |
| 01/07/1992 | NA | - | NA | Gill PG, Denham JW, Jamieson GG, Devitt PH, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol. 1992 Jul; 10(7):1037-43. | NA | Journal of Clinical Oncology |
| 01/05/1992 | NA | - | NA | Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian pattern of practice study. J Clin Oncol. 1992 May; 4(3):141-47. | NA | Journal of Clinical Oncology |
| 01/05/1992 | NA | - | NA | Hamilton CS and Denham JW. Dose normalisation and specification: from woe to go. Australas Radiol. 1992 May; 36(2):137-41. | NA | Australasian Radiology |
| 01/06/1990 | NA | - | NA | Lamb DS, Spry NA, Gray AJ, Johnson AD, Alexander SR, Dally MJ. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother Oncol. 1990 Jun; 18(2):107-16. | NA | Radiotherapy and Oncology |
| 14.02 | RAIDER | Robert Huddart, Shaista Hafeez, Clare Griffin, Ananya Choudhury, Farshad Foroudi, Isabel Syndikus, Benjamin Hindson, Amanda Webster, Helen McNair, Alison Birtle, Mohini Varughese, Ann Henry, Duncan B McLaren, Omi Parikh, Ashok Nikapota, Colin Tang, Emma Patel, Elizabeth Miles, Karole Warren-Oseni, Tomas Kron, Courtney Hill, Lara Philipps, Catalina Vassallo-Bonner, Ka Ching Cheung, Hannah Gribble, Rebecca Lewis, Emma Hall, Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial | European Urology | |||
| NOT TROG manuscripts | ||||||
| 11.01 | SUPREMO | Velikova G, Williams L, Willis S, Dixon J, Loncaster J, Hatton M, Clarke J, Kunkler I, Russell N, MRC SUPREMO trial UK investigators. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 2018 Oct. pii: S1470-2045(18)30515-1. | B | Lancet Oncology | ||
| 14.03 | EORTC 1219 | Christiaens M, Collettea S Overgaard J, Gregoired V, Kazmierska J, Castadot P, Giralt J, Grant W, Tomsej M, Bar-Deroma R, Monti A, Hurkmans C, Weber D. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiat Oncol. 2017 Jun; 123(3):424-30. | B | Radiotherapy and Oncology | ||
| VESPA | - | Miri N, Legge K, Colyvas K, Lehmann J, Vial P, Moore A, Harris M, Greer P. A remote EPID-based dosimetric TPS-planned audit of centers for clinical trials: outcomes and analysis of contributing factors. Radiat Oncol. 2018 Sep; 13:178 | QA | Radiotherapy and Oncology | ||
| 8.05 | WBRT | Williams N, Boyle F, Hong A, et al. Whole brain radiotherapy with partial hair-sparing technique - a feasibility study. Int J Radiol Radiat Ther. 2020;7(4):104?110. | C |
Earlybird registration closes 26 January.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292